This article is more than 5 years old. Information may no longer be current.

Heidelberg adds two new OCT models to Spectralis line

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

VISTA, Calif. — Two new spectral domain optical coherence tomography models with laser autofluorescence technology have been added to Heidelberg Engineering's Spectralis ophthalmic imaging device family, a press release from the company announced.

The new devices increase the offering of the BluePeak laser autofluorescence technology to five of the Spectralis models, including the "company's more economical spectral domain OCT devices," the release said.

According to Karl Csaky, MD, PhD, BluePeak laser autofluorescence measures the metabolic activity of the retinal pigment epithelium, a component of retinal function.

"Recent results from the Geographic Atrophy Progression study clearly demonstrate the need to use autofluorescence to track the progression of geographic atrophy for dry AMD patients," he said in the release. "This has attracted the interest of the pharmaceutical companies; at least 10 new therapies for dry AMD are now under clinical investigation. The combination of BluePeak and OCT will enable clinicians to potentially take advantage of these emerging therapeutics in the same way that ranibizumab and OCT changed the management of wet AMD."